Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
November 2023
in “
The journal of investigative dermatology/Journal of investigative dermatology
”
TLDR OR-101 shows promise for treating alopecia areata by improving hair growth.
The study evaluated the efficacy of OR-101, a next-generation selective JAK3/TEK inhibitor, in treating alopecia areata (AA) using 50 female humanized mice over 74 days. Results showed dose-dependent improvements in hair growth: 61% for 100 mg/kg, 23% for 60 mg/kg, and 8% for 30 mg/kg. The control group treated with dexamethasone and minoxidil (DM) showed 73% hair growth. Histological and immunohistochemical analysis revealed normalization of hair follicle morphology and restoration of immune privilege in higher doses of OR-101, similar to the DM group. The findings suggest that OR-101 could be a promising treatment for AA patients.